Literature DB >> 2503604

Transdermal delivery of levonorgestrel. IV: Evaluation of membranes.

D R Friend1, P Catz, J Heller, M Okagaki.   

Abstract

A series of experiments were performed to evaluate the flux of levonorgestrel (LN), ethyl acetate (EtAc), and ethanol (EtOH) through excised rat skin, through a variety of synthetic membranes and through membranes supported on rat skin. Using a donor phase of EtAc:EtOH (7:3) containing excess solid LN, the flux of LN through rat skin was approximately 1.0 microgramc/cm2.h. The normalized fluxes of LN, EtAc, and EtOH through ethylene vinyl acetate (EVAc) copolymers of varying vinyl acetate (VAc) content (12 to 25%) were 1.3 to 3.1 x 10(-8), 2.6 to 6.8 x 10(-4), and 4.8 to 9.9 x 10(-5) g.cm/cm2.h, respectively. Permeability experiments were also performed with the EVAc membranes supported on rat skin. By selecting the VAc content and thickness of the EVAc membranes, it was possible to control the delivery of enhancer (EtAc:EtOH) through rat skin (membrane-rate control) or to let the skin control the overall delivery of enhancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503604     DOI: 10.1002/jps.2600780612

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  Development and evaluation of α-asarone transdermal patches based on hot-melt pressure-sensitive adhesives.

Authors:  Zhenwei Yu; Yi Liang; Wenquan Liang
Journal:  AAPS PharmSciTech       Date:  2013-01-10       Impact factor: 3.246

2.  Transdermal delivery of levonorgestrel. V. Preparation of devices and evaluation in vitro.

Authors:  D R Friend; P Catz; J Heller; M Okagaki
Journal:  Pharm Res       Date:  1989-11       Impact factor: 4.200

3.  A Comparative Study of Transmembrane Diffusion and Permeation of Ibuprofen across Synthetic Membranes Using Franz Diffusion Cells.

Authors:  Shiow-Fern Ng; Jennifer Rouse; Dominic Sanderson; Gillian Eccleston
Journal:  Pharmaceutics       Date:  2010-05-18       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.